Venigalla Rao at CUA Gets Gates Foundation Grant to Develop T4 as a Vector For HIV Vaccination.
BioControl has been purchased by Targeted Genetics. Biocontrol will start to do work against bacterial infections.
OmniLytics has relocated from Salt Lake City to Sandy, Utah, US to expand its manufacturing capabilities. In 2010 OmniLytics produced nearly 100,000 litres of bacteriophage product and moving to a site with 60,000 sq ft (from 10,000) of lab and manufacturing space will support continued growth.
Justin Reber, CEO of OmniLytics, said: “This move not only significantly increases our manufacturing capabilities, but also provides the potential for future expansion onto an additional seven acres of undeveloped property acquired adjacent to the four acre, two building campus.”
OmniLytics is also nearing completion of a master plan for the production facility. This will provide equipment to support production of millions of litres of bacteriophage final product a year.
Source: http://www.in-pharmatechnologist.com/Materials-Formulation/Biopharm-manufacturing-expansion-round-up
FDA begins approving bacteriophages for MicroPhage
Excellent podcast on bacteriophages from Microbe World
In September, St. Hilda’s College at Oxford is having their first bacteriophage conference. Oxford Bacteriophage Meeting 2011.
Amplifphi Biosciences demonstrates the efficacy of Bacteriophage Therapy in a controlled setting.